In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Dutch research envisions homes made from fungus
In The Netherlands, researchers at Utrecht University have submitted a paper detailing the potential for homes to be made out of fungus.
The group evaluates...
Living, programmable robots raise ethics concerns
In Boston, researchers have created living, programmable organisms that could one day have widespread applications, including cleaning microplastics from the oceans.
Dubbed xenobots by their...
Itaconix and Nouryon terminate chelates deal
In the United Kingdom, Itaconix and chemical giant Nouryon have mutually agreed to terminate an agreement in which Nouryon exclusively distributes Itaconix’s biobased chelating...